Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Pfizer axes B7-H4 ADC, triggering $1B impairment charge
Pfizer tallied up $1.2 billion in impairment charges in response to changes in development plans and commercial forecasts for Seagen-acquired ADCs.
Nick Paul Taylor
Feb 4, 2025 8:46am
CytomX lays off 40%, mulls future of Amgen-partnered drug
Jan 7, 2025 7:56am
Fierce Biotech's top 10 editor's picks for 2024
Dec 23, 2024 3:00am
Pyxis whittles pipeline down to one clinical asset
Dec 20, 2024 6:15am
Aadi buys preclinical ADCs, sells Fyarro to reboot business
Dec 20, 2024 3:54am
Elevation lifts HER3 ADC toward clinic with $368M Synaffix deal
Dec 12, 2024 9:19am